Morgan Stanley lowered the firm’s price target on Bayer (BAYRY) to EUR 26 from EUR 30 and keeps an Equal Weight rating on the shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- BridgeBio price target raised to $49 from $48 at Scotiabank
- M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
- Bayer sees new drugs boosting return to growth in 2027, WSJ reports
- Bayer: Gadoquatrane met primary, secondary endpoints in Phase III QUANTI studies
- BridgeBio receives positive CHMP opinion for acoramidis for ATTR-CM treatment